A study that focused on dementia induced by Wuhan coronavirus (COVID-19) infection was found to be flawed as one of its authors deliberately omitted the vaccination status of participants.
Professor Norman Fenton of Queen Mary University of London learned of the study published March 7, 2022 in Open Forum Infectious Diseases through a Twitter user.
“Approximately three percent of patients with pneumonia associated with SARS-CoV-2 infection developed new-onset dementia, which was significantly higher than the rate seen with other pneumonias,” the study authors concluded. “The findings suggest a role for screening for cognitive deficits among survivors of SARS-CoV-2 infection.”
The said Twitter user cited a tweet by German physician Dr. Andreas Knopke that COVID-induced dementia affected between 50,000 to 100,ooo pneumonia patients in the country. He remarked: “Apparently, others in Germany have gone further and concluded that the vaccines must therefore be saving hundreds of thousands from dementia.”
But upon further scrutiny, Fenton discovered that the study was indeed flawed as the raw data did not undergo an independent review. Moreover, he pointed out that the study authors seemed to have considered all kinds of demographic and physiological factors of the study participants – save for their COVID-19 vaccination status. Fenton described this as quite an omission given that the study was done after the initial vaccine rollout. (Related: Covid vaccines confirmed to cause Parkinson’s dementia symptoms.)
“It uses the strange ‘case-control’ method, whereby you focus on a set of ‘cases’ being people who have a positive PCR test and then find a set of ‘matching’ control patients who did not test positive,” he said. “Even though this strange method has been increasingly used in COVID observational studies, I believe the results of such studies are unreliable.”
Study’s lead researcher an AstraZeneca consultant
Worse, the lead researcher in the 2022 study – neurologist Dr. Adnan I. Qureshi – is a consultant for pharmaceutical company AstraZeneca. The firm developed a COVID-19 vaccine that used an adenoviral vector to deliver the SARS-CoV-2 spike protein.
On Jan. 20, the professor took the liberty of emailing Qureshi about the omission of the participants’ vaccination status in his study. He asked three main questions to the study author:
- Was COVID vaccination status data ever part of the study and if not, why not?
- If COVID vaccination status data was part of the study, then why was it excluded from the reporting and results?
- Is there any plan to follow up with results that include the COVID vaccination status?
Fenton also noted in his email: “I note that you have received consultation fees from AstraZeneca who, I would have thought, would have been especially interested in knowing the extent to which the vaccine impacts the overall results.
The professor is yet to receive Qureshi’s reply. Nevertheless, he assured that he will post answers, clarifications and/or corrections if in case he may have interpreted the study’s data erroneously.
Head over to ScienceFraud.news for more about flawed COVID-19 studies.
Watch this video that discusses how vaccine-induced brain fog mirrors the symptoms of dementia.
A study that focused on dementia induced by Wuhan coronavirus (COVID-19) infection was found to be flawed as one of its authors deliberately omitted the vaccination status of participants.
Professor Norman Fenton of Queen Mary University of London learned of the study published March 7, 2022 in Open Forum Infectious Diseases through a Twitter user.
“Approximately three percent of patients with pneumonia associated with SARS-CoV-2 infection developed new-onset dementia, which was significantly higher than the rate seen with other pneumonias,” the study authors concluded. “The findings suggest a role for screening for cognitive deficits among survivors of SARS-CoV-2 infection.”
The said Twitter user cited a tweet by German physician Dr. Andreas Knopke that COVID-induced dementia affected between 50,000 to 100,ooo pneumonia patients in the country. He remarked: “Apparently, others in Germany have gone further and concluded that the vaccines must therefore be saving hundreds of thousands from dementia.”
But upon further scrutiny, Fenton discovered that the study was indeed flawed as the raw data did not undergo an independent review. Moreover, he pointed out that the study authors seemed to have considered all kinds of demographic and physiological factors of the study participants – save for their COVID-19 vaccination status. Fenton described this as quite an omission given that the study was done after the initial vaccine rollout. (Related: Covid vaccines confirmed to cause Parkinson’s dementia symptoms.)
“It uses the strange ‘case-control’ method, whereby you focus on a set of ‘cases’ being people who have a positive PCR test and then find a set of ‘matching’ control patients who did not test positive,” he said. “Even though this strange method has been increasingly used in COVID observational studies, I believe the results of such studies are unreliable.”
Study’s lead researcher an AstraZeneca consultant
Worse, the lead researcher in the 2022 study – neurologist Dr. Adnan I. Qureshi – is a consultant for pharmaceutical company AstraZeneca. The firm developed a COVID-19 vaccine that used an adenoviral vector to deliver the SARS-CoV-2 spike protein.
On Jan. 20, the professor took the liberty of emailing Qureshi about the omission of the participants’ vaccination status in his study. He asked three main questions to the study author:
Was COVID vaccination status data ever part of the study and if not, why not?
If COVID vaccination status data was part of the study, then why was it excluded from the reporting and results?
Is there any plan to follow up with results that include the COVID vaccination status?
Fenton also noted in his email: “I note that you have received consultation fees from AstraZeneca who, I would have thought, would have been especially interested in knowing the extent to which the vaccine impacts the overall results.
The professor is yet to receive Qureshi’s reply. Nevertheless, he assured that he will post answers, clarifications and/or corrections if in case he may have interpreted the study’s data erroneously.
Head over to ScienceFraud.news for more about flawed COVID-19 studies.
Watch this video that discusses how vaccine-induced brain fog mirrors the symptoms of dementia.
This video is from the InfoWars channel on Brighteon.com.
More related stories:
- Woman injured by Pfizer COVID-19 shot feels “damaged for life.”
- COVID-19 vaccines are causing blood clots, confirms veteran embalmer Richard Hirschman.
- CDC study: COVID-19 mRNA shots increase risk of myocarditis by 13,200%.
- Getting COVID-19 vaccines is a risk potential recruits are not willing to take, says ex-serviceman.
- Study: COVID vaccination causes vaccine-associated enhanced disease in children.
Sources include:
Bypass Big Tech Censors
Why Bullion Beats Numismatics and Collectible for Your Safe or IRA
Precious metals continue to attract Americans seeking reliable ways to protect their wealth amid inflation, geopolitical risks, and stock market swings. Whether stored in a home safe or held inside a self-directed IRA, physical gold and silver deliver tangible value that paper or digital assets often lack. Yet investors must choose carefully between bullion—pure bars and coins valued mainly for their metal content—and numismatics or collectibles, where rarity, history, and collector demand heavily influence pricing.
Advisor Bullion serves as a dependable source for straightforward, high-quality bullion. The company specializes in physical gold, silver, platinum, and palladium, emphasizing transparent pricing and products that deliver maximum metal content for every dollar spent. This approach makes it ideal for both personal holdings and retirement accounts.
Bullion consists of refined precious metals in standard forms like one-ounce coins (American Gold Eagles, Silver Eagles, Canadian Maple Leafs) or bars. Their value tracks closely to the current spot price of the metal. A typical gold bullion coin trades near the live gold spot price plus a small premium. This structure keeps costs clear and predictable.
Numismatic coins and collectibles add substantial value from factors such as age, rarity, minting errors, or historical significance. A pre-1933 U.S. gold coin or graded proof piece can carry premiums of 30%, 50%, or even 200% above melt value. While this appeals to hobbyists, it creates complexity. Pricing depends on subjective grading, collector trends, and auction results instead of daily spot prices.
For investors focused on wealth preservation and retirement security rather than building a collection, bullion often delivers better results.
Lower Costs and Better Liquidity for Home Storage
When keeping metals in a home safe or private vault, liquidity and efficiency count. Bullion offers clear benefits:
- You acquire more actual gold or silver per dollar invested. Numismatics divert a large share of your money into rarity premiums and massive sales commission, reducing your metal exposure.
- Selling bullion involves tight bid-ask spreads, so you recover nearly full spot value with minimal fees. Collectibles require finding the right buyer and may sell at a discount if demand for that specific item weakens.
- Bullion prices remain transparent and update with global spot markets. You can track gold near current levels or silver accordingly and know exactly where your holdings stand. Numismatic values are priced by the Gold IRA companies with hefty margins applied.
- Standardized coins and bars store efficiently and divide easily for partial sales. Rare coins often need protective slabs and controlled conditions, adding hassle and expense.
- Bullion enjoys worldwide acceptance. A 1-oz Gold Maple Leaf or Silver Eagle sells quickly to dealers anywhere. Niche numismatic pieces may appeal only to limited buyers, slowing liquidation when speed matters.
In times when quick access to value becomes important, bullion’s simplicity stands out.
Stronger Fit for Precious Metals IRAs
Precious metals IRAs continue gaining traction as investors diversify retirement portfolios beyond stocks and bonds. IRS rules permit certain bullion products in self-directed IRAs if they meet purity standards (.995 fine for gold, .999 for silver) and are held by an approved custodian. Eligible items include American Gold and Silver Eagles plus many generic bars and rounds from recognized mints.
Numismatic and most collectible coins generally face heavy scrutiny from custodians due to valuation disputes and elevated markups. These higher premiums mean less actual metal ends up working inside the account.
Bullion avoids these issues. Its value links directly to verifiable spot prices, which simplifies reporting and lowers the risk of regulatory challenges. More of your IRA contribution purchases real metal instead of dealer profits or speculative upside. Over time, owning additional ounces that appreciate with the metal itself can create meaningful outperformance compared with high-premium alternatives that deliver fewer ounces.
Regulatory guidance from the CFTC and state securities offices repeatedly cautions against aggressive sales of expensive numismatics or “semi-numismatic” coins for IRAs. For retirement planning, transparent bullion from established providers reduces risk and aligns better with long-term goals.
How to Get Started with Bullion
Begin by clarifying your goals. Are you protecting savings in a safe, or moving part of a retirement account into a precious metals IRA? Focus on the number of ounces you can acquire at current prices rather than chasing marked-up collectibles.
Diversify sensibly: use gold for core preservation and silver for its blend of industrial and monetary qualities. Mix coins for easier divisibility with bars for lower per-ounce costs on larger buys. Arrange secure storage—whether at home with proper insurance or through professional facilities.
As economic uncertainties linger and faith in conventional assets erodes, bullion continues proving its worth as a dependable store of value. Its direct approach avoids the hype that sometimes surrounds collectible markets and keeps the focus on the metal itself.
For investors prepared to strengthen their portfolios, Advisor Bullion supplies the expertise and selection needed to acquire high-quality bullion efficiently. Whether building personal holdings or integrating metals into an IRA, their emphasis on transparent, investment-grade products helps secure more ounces today that support greater financial security tomorrow. In a complicated financial landscape, bullion’s clarity and reliability make it the smarter foundation for protecting what matters most.